These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 22014845

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Continuous broad protection against osteoporotic fractures with strontium ranelate.
    Ferrari S.
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv20-4. PubMed ID: 19783590
    [Abstract] [Full Text] [Related]

  • 24. [Strontium ranelate (Osseor)--unique double mechanism--physiologic bone treatment as live tissue].
    Novak S.
    Reumatizam; 2007 Oct; 54(2):83-4. PubMed ID: 18351151
    [No Abstract] [Full Text] [Related]

  • 25. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.
    Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ.
    J Clin Endocrinol Metab; 2005 May; 90(5):2816-22. PubMed ID: 15728210
    [Abstract] [Full Text] [Related]

  • 26. [Strontium ranelate and non-vertebral fracture in postmenopausal osteoporosis].
    Callejas Rubio JL, López Pérez L, Sánchez Cano D, Ortego Centeno N.
    Med Clin (Barc); 2006 Jul 15; 127(7):279. PubMed ID: 16942738
    [No Abstract] [Full Text] [Related]

  • 27. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
    Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C, Balogh A, Delmas PD, Meunier PJ.
    Arthritis Rheum; 2008 Jun 15; 58(6):1687-95. PubMed ID: 18512789
    [Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
    Hiligsmann M, Bruyère O, Reginster JY.
    Bone; 2010 Feb 15; 46(2):440-6. PubMed ID: 19716940
    [Abstract] [Full Text] [Related]

  • 29. New findings with old drugs for osteoporosis.
    Doggrell SA.
    Expert Opin Pharmacother; 2009 Feb 15; 10(3):513-6. PubMed ID: 19191686
    [Abstract] [Full Text] [Related]

  • 30. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
    Seeman E.
    Curr Opin Rheumatol; 2006 Jun 15; 18 Suppl 1():S17-20. PubMed ID: 16735841
    [Abstract] [Full Text] [Related]

  • 31. Strontium ranelate for osteoporosis?
    Drug Ther Bull; 2006 Apr 15; 44(4):29-32. PubMed ID: 16617933
    [Abstract] [Full Text] [Related]

  • 32. Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions.
    Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L.
    Br J Clin Pharmacol; 2008 Nov 15; 66(5):689-94. PubMed ID: 18754840
    [Abstract] [Full Text] [Related]

  • 33. Strontium ranelate for osteoporosis in men. More dangerous than beneficial.
    Prescrire Int; 2013 Jun 15; 22(139):150. PubMed ID: 23866350
    [Abstract] [Full Text] [Related]

  • 34. Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England.
    Osborne V, Layton D, Perrio M, Wilton L, Shakir SA.
    Drug Saf; 2010 Jul 01; 33(7):579-91. PubMed ID: 20553059
    [Abstract] [Full Text] [Related]

  • 35. Strontium is incorporated into mineral crystals only in newly formed bone during strontium ranelate treatment.
    Li C, Paris O, Siegel S, Roschger P, Paschalis EP, Klaushofer K, Fratzl P.
    J Bone Miner Res; 2010 May 01; 25(5):968-75. PubMed ID: 19874195
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial.
    Cooper C, Reginster JY, Chapurlat R, Christiansen C, Genant H, Bellamy N, Bensen W, Navarro F, Badurski J, Nasonov E, Chevalier X, Sambrook PN.
    Curr Med Res Opin; 2012 Feb 01; 28(2):231-9. PubMed ID: 22148897
    [Abstract] [Full Text] [Related]

  • 37. [Rash and renal failure secondary to strontium ranelate].
    Paz Yepes M, Rodríguez Castilla J.
    Med Clin (Barc); 2010 Jan 30; 134(2):85-6. PubMed ID: 19423139
    [No Abstract] [Full Text] [Related]

  • 38. [Osteoporosis].
    Buck G, Perger L, Bischoff-Ferrari HA.
    Praxis (Bern 1994); 2011 Jul 06; 100(14):821-32. PubMed ID: 21732293
    [No Abstract] [Full Text] [Related]

  • 39. Bullous DRESS in a patient on strontium ranelate.
    Kramkimel N, Sibon C, Le Beller C, Saiag P, Mahé E.
    Clin Exp Dermatol; 2009 Oct 06; 34(7):e349-50. PubMed ID: 19456761
    [No Abstract] [Full Text] [Related]

  • 40. Strontium ranelate--does it affect the management of postmenopausal osteoporosis?
    Winzenberg T, Powell S, Jones G.
    Aust Fam Physician; 2007 Aug 06; 36(8):631-2. PubMed ID: 17676187
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.